How are energy investors positioned?
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CEO Jeremy Bender recently executed a series of stock transactions, according to an SEC filing. The company, currently valued at $1.25 billion, shows a strong financial position according to InvestingPro data, with more cash than debt on its balance sheet. On February 15, 2025, Bender acquired a total of 31,686 shares of common stock through the conversion of restricted stock units, with no cash changing hands.
Subsequently, on February 18, 2025, Bender sold 12,048 shares at an average price of $11.963 per share, generating approximately $144,130. This sale was conducted to cover tax liabilities associated with the settlement of the restricted stock units. Following these transactions, Bender holds 128,015 shares directly. The stock, which trades near InvestingPro’s Fair Value estimate, has shown resilience with a current ratio of 14.62, indicating strong liquidity. Investors should note that Day One is scheduled to report earnings on February 25, 2025. InvestingPro subscribers have access to 4 additional key insights about DAWN’s financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.